Scoring Method to Identify Low HCC Risk in Patients With Advanced Fibrosis After SVR to HCV Therapy

November 8-12, 2019; Boston, Massachusetts
External validation supports scoring system for identifying patients with low risk of HCC following SVR.
Format: Microsoft PowerPoint (.ppt)
File Size: 172 KB
Released: November 18, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AbbVie
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.

Related Content

From Clinical Care Options (CCO), download a PDF featuring expert discussion on using immunotherapy for patients with advanced HCC

Lipika Goyal, MD Amit G. Singal, MD, MS Released: January 22, 2021

From Clinical Care Options (CCO), download a PDF featuring expert answers to clinician questions on using immunotherapy for patients with advanced HCC

Lipika Goyal, MD Amit G. Singal, MD, MS Released: January 21, 2021

CCO module by Dr. Mark Sulkowski on optimal HCV management in PWID, children, liver transplant recipients and patients with renal disease or HIV

Stefan Zeuzem, MD
Program Director
Mark S. Sulkowski, MD
Released: December 28, 2020

CCO commentary from Paul Y. Kwo, MD, on new HBV treatment and management data presented at AASLD 2020 Virtual

Paul Y. Kwo, MD Released: December 21, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue